Silo Pharma Announces Positive Research Results on Depression Treatment

LOS ANGELES-Silo Pharma, Inc., a biopharmaceutical company specializing in novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, has announced new research findings indicating promising advances in depression remission and relapse prevention.

Innovative Drug Formulation

The study, conducted under Silo Pharma’s sponsored research agreement with Columbia University, explored a new drug formulation targeting previously unexplored biochemical pathways associated with mood regulation. The results demonstrated significant improvements in patient mood stability without the common side effects associated with current antidepressants.

“The recently completed study demonstrated marked improvements in mood stability, which we see as a potentially significant development for combatting depression and preventing relapse,” said Silo CEO Eric Weisblum. “While advancing our SPC-15 program in PTSD to the clinic remains our top pipeline priority, we are excited about these encouraging new results and the additional potential for treating millions of people affected by depression which could ultimately expand our pipeline.”

Advancing SPC-15 for PTSD

In addition to the new depression treatment findings, Silo Pharma is progressing with its SPC-15 program, which targets PTSD. The company has successfully completed pre-clinical development and is preparing to submit a pre-Investigational New Drug (IND) application to the FDA. Silo Pharma has exercised its option to license SPC-15 from Columbia University, with an exclusive license agreement expected to be finalized in the first half of 2024.

Future Prospects

This recent study adds a significant potential therapy to Silo Pharma’s pipeline, highlighting the company’s commitment to innovative treatments for mental health disorders. The promising results from the depression study may pave the way for further development and commercialization, offering new hope for millions affected by depression.